Clinical trials: Migraines
Migraine
A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches
The purpose of this study is to evaluate the long-term safety of almotriptan malate (a migraine headache medication) in the treatment of migraine headaches in adolescents for up to one year.
- Trial name
- NCT00257010
- Testing
- Almotriptan Malate
- Where
- 49 sites in United States
- Volunteers
- 447 people
- Sponsor
- Janssen-Ortho LLC
Chronic Migraine
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine
The purpose of this study is to evaluate the safety, tolerability, and changes in the number of migraine and headache days with repeated subcutaneous administration of IONIS-PKKRx (ISIS 546254) or placebo in subjects with chronic…
- Trial name
- NCT03108469
- Testing
- IONIS-PKKRx (ISIS 546254)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Smith, Timothy R., M.D.
Migraine
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.
- Trial name
- NCT03076970
- Testing
- lasmiditan 200 mg, Sumatriptan
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM).
- Trial name
- NCT04464707
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 292 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
Although many adults with migraines use non-pharmacological treatment options, there is a lack of research on the use of many mind/body techniques specifically for headache.
- Trial name
- NCT02695498
- Testing
- Mindfulness Based Stress Reduction, Migraine/stress Education
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Wake Forest University Health Sciences
Insomnia, Migraine
Treatment of Insomnia in Migraineurs
It is hypothesized that treating insomnia in migraineurs, many of whom also have tension headaches, prolongs total sleep time to the extent that it decreases overall headache frequency.
- Trial name
- NCT00812214
- Testing
- eszopiclone
- Volunteers
- 113 people
- Sponsor
- MedVadis Research Corporation
Migraine Disorder
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
- Trial name
- PREVAIL (NCT02985398)
- Testing
- ALD403 (Eptinezumab)
- Where
- 20 sites in United States
- Volunteers
- 128 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.
- Trial name
- NCT00432237
- Testing
- MK0974 50 mg, MK0974 150 mg, MK0974 300 mg
- Volunteers
- 1,703 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Migraine
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
- Trial name
- NCT03855137
- Testing
- Atogepant 30 mg, Atogepant 60 mg
- Where
- 150 sites in United States, Australia and 15 more
- Volunteers
- 778 people
- Sponsor
- Allergan
Migraine
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
This will be a randomized, single dose, double-blind, placebo-controlled, Latin-square design with 5-period (full) crossover study with participants randomized to treatment sequences. Participants will complete all 5 Periods.
- Trial name
- NCT03012334
- Testing
- Lasmiditan, Alprazolam
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine Headache
Drug and Non-Drug Treatment Of Severe Migraine
The purpose of this study is to determine if the addition of preventive medication, behavior migraine management or the combination of preventive medication and behavior migraine management improves the outcome of optimal acute…
- Trial name
- TSM (NCT00910689)
- Testing
- Propranolol or nadolol, Behavioral Migraine Management (BMM), Optimal Acute Therapy
- Where
- 2 sites in United States
- Volunteers
- 232 people
- Sponsor
- Ohio University
Migraine Headache
Low-dose Propofol for Pediatric Migraine
Propofol, a general anesthetic, has been suggested to be effective for the treatment of migraine headaches in adults when used in subanesthetic doses (lower doses than those used for anesthesia or sedation).
- Trial name
- NCT01604785
- Testing
- Propofol, Standard Treatment
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Oregon Health and Science University
Migraine
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
- Trial name
- NCT03670810
- Testing
- Lasmiditan
- Where
- 141 sites in United States, Austria and 15 more
- Volunteers
- 1,633 people
- Sponsor
- Eli Lilly and Company
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
Metformin for the Prevention of Episodic Migraine (MPEM)
The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.
- Trial name
- MPEM (NCT02593097)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Migraine
Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches
The purpose of this research is to assess how well the Avulux® migraine lenses work in reducing the impact of migraine headaches as measured by improvement in an 11-point pain scale after two and four hours of device application…
- Trial name
- NCT04341298
- Testing
- 11-point pain scale, Headache diary, Avulux®
- Where
- 3 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Avulux, Inc.
Migraine
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.
- Trial name
- NCT02614287
- Testing
- Galcanezumab
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Eli Lilly and Company
Episodic Migraine
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.
- Trial name
- NCT02176018
- Testing
- Dextromethorphan and quinidine
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- Cady, Roger, M.D.